Standout Papers

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-lab... 2020 2026 2022 2024409
  1. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial (2020)
    Catherine A. Shu, Justin F. Gainor et al. The Lancet Oncology
  2. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors (2024)
    Sarah Cook, Daniel E. Meyers et al. JAMA Network Open

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 59 standout
Sub-graph 1 of 23

Citing Papers

Cancer statistics, 2025
2025 Standout
Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
2025 Standout
2 intermediate papers

Works of Aliyah Pabani being referenced

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
2020 Standout

Author Peers

Author Last Decade Papers Cites
Aliyah Pabani 596 511 81 31 763
Hayato Kawachi 541 423 81 35 693
Toshiro Yonei 530 494 90 28 831
Takatoshi Fujishita 543 362 101 32 775
Iveta Kudaba 605 468 94 22 710
Paul Taylor 346 540 61 31 871
Akira Haro 368 440 100 41 737
Marco Angelo Burgio 647 490 61 44 840
Suchita Pakkala 670 509 98 32 948
Junxun Ma 576 359 90 44 765
Yasuto Yoneshima 638 451 59 54 881

All Works

Loading papers...

Rankless by CCL
2026